These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 12073254)

  • 1. [Reactions and complications caused by thrombocyte concentrate transfusions].
    Haĭdukova SM; Vydyborets' SV; Kostiukova NI
    Lik Sprava; 2002; (2):3-11. PubMed ID: 12073254
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Platelet transfusions.
    Stroncek DF; Rebulla P
    Lancet; 2007 Aug; 370(9585):427-38. PubMed ID: 17679020
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Platelet transfusion therapy.
    Slichter SJ
    Hematol Oncol Clin North Am; 2007 Aug; 21(4):697-729, vii. PubMed ID: 17666286
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical evaluation of transfusion of prestorage-leukoreduced apheresis platelets.
    Ogawa Y; Wakana M; Tanaka K; Oka K; Aso H; Hayashi M; Seno T; Ishida T; Nomura S; Fukuhara S
    Vox Sang; 1998; 75(2):103-9. PubMed ID: 9784662
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Blood transfusion preparations with a low leukocyte count. I. Preparation of thrombocyte concentrates from buffy coats].
    Gasová Z; Turek P
    Cas Lek Cesk; 1992 Dec; 131(24-25):754-5. PubMed ID: 1288879
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Thrombocyte concentrates prepared from the buffy coat. A modified method].
    Gasová Z; Turek P
    Cas Lek Cesk; 1996 Jan; 135(3):89-91. PubMed ID: 8625376
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Thrombocyte substitution, 2: Thrombocyte preparations and determining the effectiveness of thrombocyte transfusion].
    Anders O; Preussner S; Konrad H
    Z Gesamte Inn Med; 1986 Dec; 41(23):647-51. PubMed ID: 3577256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Coagulopathy in trauma patients: importance of thrombocyte function?
    Davenport RA; Brohi K
    Curr Opin Anaesthesiol; 2009 Apr; 22(2):261-6. PubMed ID: 19390252
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platelet efficacy revisited?
    Rebulla P
    Transfusion; 2010 Apr; 50(4):745-7. PubMed ID: 20398142
    [No Abstract]   [Full Text] [Related]  

  • 10. Pathogen-inactivation of platelet components with the INTERCEPT Blood System ™: a cohort study.
    Infanti L; Stebler C; Job S; Ruesch M; Gratwohl A; Irsch J; Lin L; Buser A
    Transfus Apher Sci; 2011 Oct; 45(2):175-81. PubMed ID: 21840762
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biological aspects of the effectiveness/ineffectiveness of thrombocyte transfusions].
    Nagy S; Rácz Z
    Orv Hetil; 2001 Nov; 142(44):2415-20. PubMed ID: 11766234
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ABO incompatible platelets: risks versus benefit.
    Dunbar NM; Ornstein DL; Dumont LJ
    Curr Opin Hematol; 2012 Nov; 19(6):475-9. PubMed ID: 22914587
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytokines and related molecules, and adverse reactions related to platelet concentrate transfusions.
    Cognasse F; Garraud O
    Transfus Clin Biol; 2019 Sep; 26(3):144-146. PubMed ID: 31327557
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Platelet transfusion therapy: platelet concentrate preparation and storage.
    Lee VS; Tarassenko L; Bellhouse BJ
    J Lab Clin Med; 1988 Apr; 111(4):371-83. PubMed ID: 3280712
    [No Abstract]   [Full Text] [Related]  

  • 15. [The significance of the thrombocyte crossmatching test].
    Korínková P; Vítek A; Prazák J; Sejkorová J
    Cas Lek Cesk; 1990 Dec; 129(51):1621-4. PubMed ID: 2076527
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Platelet transfusion refractoriness.
    Hod E; Schwartz J
    Br J Haematol; 2008 Jul; 142(3):348-60. PubMed ID: 18510692
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Determination of predictors of severity for recipient adverse reactions during platelet product transfusions.
    Sut C; Tariket S; Cognasse F; Garraud O
    Transfus Clin Biol; 2017 Jun; 24(2):87-91. PubMed ID: 28479028
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment.
    Osselaer JC; Messe N; Hervig T; Bueno J; Castro E; Espinosa A; Accorsi P; Junge K; Jacquet M; Flament J; Corash L
    Transfusion; 2008 Jun; 48(6):1061-71. PubMed ID: 18346019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Platelet transfusions: treatment options for hemorrhage secondary to thrombocytopenia.
    Hux BD; Martin LG
    J Vet Emerg Crit Care (San Antonio); 2012 Feb; 22(1):73-80. PubMed ID: 23016744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Buffy-coat-derived pooled platelet concentrates and apheresis platelet concentrates: which product type should be preferred?
    Schrezenmeier H; Seifried E
    Vox Sang; 2010 Jul; 99(1):1-15. PubMed ID: 20059760
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.